Predictors of response and long-term efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

Seminars in Arthritis and Rheumatism · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles